MARIETTA, Ga., Sept. 8, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will be hosting and webcasting its Analyst Day on Tuesday, October 14, 2014, in New York, New York. Parker H. “Pete” Petit, Chairman and CEO; William C. Taylor, President and COO; Michael J. Senken, Chief Financial Officer; and other members of MiMedx senior management will present and be on hand to participate in questions and answers.
The Analyst Day presentations will provide investors with a comprehensive overview of the scientific foundation and clinical results of the Company’s allografts; discussion of current financial results and projections; and updates on the progress of strategic initiatives involving reimbursement, informatics, protection of intellectual property, production efficiencies, expansion of sales channels, penetration of key market segments, product development and marketing plans.
In-person attendance at the presentations will be by invitation only. The webcast will be a listen-only simulcast of the presentations beginning at 10:00 AM Eastern Daylight Time and concluding at 2:00 PM Eastern Daylight Time. The webcast will be suspended for approximately 45 minutes for a mid-day lunch break. The webcast will be available on-line at the Company’s website, www.mimedx.com. An on-line replay will be available approximately one hour following the conclusion of the live webcast. The replay can also be found on the Company’s website at www.mimedx.com.
About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 275,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
SOURCE MiMedx Group, Inc.
Help employers find you! Check out all the jobs and post your resume.